Philadelphia Chromosome

Known as: Chromosome, Philadelphia, Ph 1 Chromosomes, Philadelphia Chromosome [Disease/Finding] 
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22… (More)
National Institutes of Health

Related topics

Related topics

39 relations
ABL1 geneB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeBCR geneBlast Phase
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
BACKGROUND Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the… (More)
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
BACKGROUND Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • table 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3…
BACKGROUND Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive… (More)
  • table 1
  • table 2
  • table 2
  • table 3
  • figure 1
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Imatinib mesylate, an inhibitor of the Bcr-Abl tyrosine kinase, has modest activity in refractory/relapsed Philadelphia… (More)
  • table 1
  • table 2
  • table 2
  • table 2
  • figure 1
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
BACKGROUND BCR-ABL, a constitutively activated tyrosine kinase, is the product of the Philadelphia chromosome. This enzyme is… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
The BCR/ABL oncogenic tyrosine kinase is responsible for initiating and maintaining the leukemic phenotype of Philadelphia… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
In tumor cells from virtually all patients with chronic myelogenous leukemia, the Philadelphia chromosome, a fusion of… (More)
Is this relevant?
Highly Cited
1983
Highly Cited
1983
Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
The localization of cellular oncogenes near the break points of tumour-specific chromosomal aberrations suggests an involvement… (More)
Is this relevant?